Private Equity

Animal Health and Life Sciences offer Private Equity companies attractive characteristics: durable demand, recession-resilient growth, fragmentation in many sub-sectors, and clear value creation levers through commercial excellence, buy-and-build, and operational improvement. The global Animal Health market is projected to grow from approximately USD 44 billion in 2025 to USD 57 billion by 2030, with even faster growth in segments like companion animal therapeutics, veterinary services, diagnostics, and pet nutrition - making it one of the most actively pursued specialist sectors in healthcare Private Equity today.

Commercial Due Diligence (CDD) is the independent assessment of a target company's market attractiveness, competitive position, and growth sustainability - the analysis that ultimately validates or challenges the investment thesis. For companies investing in Animal Health and Life Sciences, sector-specific CDD matters because the value drivers are often subtle: species-level demand patterns, veterinary channel economics, generic erosion timelines, regulatory pathways, and customer behavior that generalist diligence providers frequently miss or misread. Strong CDD compresses risk, sharpens valuation, and surfaces the value creation levers that drive returns post-close.

Buy-side CDD is commissioned by a prospective acquirer (typically a Private Equity sponsor) to independently validate the investment case before bidding. Vendor Due Diligence (VDD) is commissioned by the seller - usually ahead of a competitive auction - to provide all bidders with a credible, independent commercial view of the asset, accelerating the process and supporting valuation. Both require the same analytical rigor, but VDD must additionally withstand scrutiny from multiple bidders and their advisors, making sector credibility especially important.

Buy-and-build in Animal Health is most active in fragmented sub-sectors such as veterinary clinic consolidation, veterinary diagnostics, animal MedTech, and specialty distribution. We support sponsors across the full buy-and-build lifecycle - generating the complete target universe within a defined sector, screening for strategic and cultural fit, profiling individual targets, supporting initial outreach and relationship building, and providing commercial due diligence on platform and add-on transactions. Post-acquisition, we help portfolio companies integrate add-ons, harmonize commercial models, and capture revenue and cost synergies.

Effective value creation begins before the deal closes, with a clear translation of the investment thesis into a 100-day plan and a multi-year value creation roadmap. Post-close, common workstreams include pricing transformation, sales force sizing and territory optimization, customer segmentation, multi-channel commercial model design, go-to-market acceleration for pipeline products, and buy-and-build integration. The objective is to compress time to value and close the gap between deal-model assumptions and operational reality - which is where many sponsors find that sector-specialist support significantly outperforms generalist alternatives.

We work with 70% of the top 20 global Private Equity firms active in healthcare, alongside specialist mid-cap funds, lower-mid-cap sponsors, family offices, and growth equity investors focused on Animal Health, Life Sciences, and adjacent Healthcare segments. Our engagements range from single-asset commercial due diligence through multi-year platform support, and we maintain strict confidentiality protocols across competing sponsors operating in the same sub-sectors.